secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2024-05-24T23:59:59+00:00
Accession:  0001601485-24-000037
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio reports preliminary Phase 1a data for ELI-002 7P: 100% T cell response, biomarker reductions
--------------------------------------------------------------------------------

- ELI-002 7P generated mKRAS-specific T cell response in 100% (11/11) evaluable patients; responses against all mutations enrolled.
- At 4.9 mg RP2D, 66.7% (4/6) had both CD8+ and CD4+ responses; biomarker reductions in 71% (5/7) evaluable patients.
- Antigen-spreading observed: T cell responses targeting non-immunizing tumor neoantigens in 100% (6/6) at RP2D.
- No dose-limiting toxicities, no treatment-related serious adverse events or cytokine release syndrome.
- Recommended Phase 2 dose: 4.9 mg AMP-Peptides 7P with 10 mg AMP-CpG-7909.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000037/0001601485-24-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000037/angn-20240523.htm
  HTML page:      https://secwatch.observer/filing/0001601485-24-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer